Abstract
Tight glycemic control in individuals with diabetes mellitus is essential to prevent or delay its complications1. Present treatments to reduce hyperglycemia mainly target the ATP-sensitive K+ (KATP) channel of pancreatic beta cells to increase insulin secretion. These current approaches are often associated with the side effect of hypoglycemia. Here we show that inhibition of the activity of cyclin-dependent kinase 5 (Cdk5) enhanced insulin secretion under conditions of stimulation by high glucose but not low glucose in MIN6 cells and pancreatic islets. The role of Cdk5 in regulation of insulin secretion was confirmed in pancreatic beta cells deficient in p35, an activator of Cdk5. p35-knockout mice also showed enhanced insulin secretion in response to a glucose challenge. Cdk5 kinase inhibition enhanced the inward whole-cell Ca2+ channel current and increased Ca2+ influx across the L-type voltage-dependent Ca2+ channel (L-VDCC) upon stimulation with high glucose in beta cells, but had no effect on Ca2+ influx without glucose stimulation. The inhibitory regulation by Cdk5 on the L-VDCC was attributed to the phosphorylation of loop II-III of the α1C subunit of L-VDCC at Ser783, which prevented the binding to SNARE proteins and subsequently resulted in a decrease of the activity of L-VDCC. These results suggest that Cdk5/p35 may be a drug target for the regulation of glucose-stimulated insulin secretion.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Moller, D.E. New drug targets for type 2 diabetes and the metabolic syndrome. Nature 414, 821–827 (2001).
Inagaki, N. et al. Reconstitution of IKATP: an inward rectifier subunit plus the sulfonylurea receptor. Science 270, 1166–1170 (1995).
Bratanova-Tochkova, T.K. et al. Triggering and augmentation mechanisms, granule pools, and biphasic insulin secretion. Diabetes 51, S83–S90 (2002).
Tsai, L.H., Takahashi, T., Caviness, V.S. Jr . & Harlow, E. Activity and expression pattern of cyclin-dependent kinase 5 in the embryonic mouse nervous system. Development 119, 1029–1040 (1993).
Lew, J. et al. A brain-specific activator of cyclin-dependent kinase 5. Nature 371, 423–426 (1994).
Tsai, L.H., Delalle, I., Caviness, V.S. Jr ., Chae, T. & Harlow, E. p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5. Nature 371, 419–423 (1994).
Tang, D. et al. An isoform of the neuronal cyclin-dependent kinase 5 (Cdk5) activator. J. Biol. Chem. 270, 26897–26903 (1995).
Ubeda, M., Kemp, D.M. & Habener, J.F. Glucose-induced expression of the cyclin-dependent protein kinase 5 activator p35 involved in Alzheimer's disease regulates insulin gene transcription in pancreatic beta-cells. Endocrinology 145, 3023–3031 (2004).
Lilja, L. et al. Cyclin-dependent kinase 5 associated with p39 promotes Munc18–1 phosphorylation and Ca2+-dependent exocytosis. J. Biol. Chem. 279, 29534–29541 (2004).
Vesely, J. et al. Inhibition of cyclin-dependent kinases by purine analogues. Eur. J. Biochem. 224, 771–786 (1994).
Ozaki, N. et al. cAMP-GEFII is a direct target of cAMP in regulated exocytosis. Nat. Cell Biol. 2, 805–811 (2000).
Ohshima, T. et al. Synergistic contributions of cyclin-dependant kinase 5/p35 and Reelin/Dab1 to the positioning of cortical neurons in the developing mouse brain. Proc. Natl. Acad. Sci. USA 98, 2764–2769 (2001).
Chae, T. et al. Mice lacking p35, a neuronal specific activator of Cdk5, display cortical lamination defects, seizures, and adult lethality. Neuron 18, 29–42 (1997).
Tomizawa, K. et al. Cdk5/p35 regulates neurotransmitter release through phosphorylation and downregulation of P/Q-type voltage-dependent calcium channel activity. J. Neurosci. 22, 2590–2597 (2002).
Schulla, V. et al. Impaired insulin secretion and glucose tolerance in β cell-selective CaV1.2 Ca2+ channel null mice. EMBO J. 22, 3844–3854 (2003).
Wiser, O., Bennett, M.K. & Atlas, D. Functional interaction of syntaxin and SNAP-25 with voltage-sensitive L- and N-type Ca2+ channels. EMBO J. 15, 4100–4110 (1996).
Yokoyama, C.T., Sheng, Z.H. & Catterall, W.A. Phosphorylation of the synaptic protein interaction site on N-type calcium channels inhibits interactions with SNARE proteins. J. Neurosci. 17, 6929–6938 (1997).
Lilla, V. et al. Differential gene expression in well-regulated and dysregulated pancreatic β-cell (MIN6) sublines. Endocrinology 144, 1368–1379 (2003).
Minami, K. et al. Insulin secretion and differential gene expression in glucose-responsive and -unresponsive MIN6 sublines. Am. J. Physiol. Endocrinol. Metab. 279, E773–781 (2000).
Wollheim, C.B., Meda, P. & Halban, P.A. Isolation of pancreatic islets and primary culture of the intact microorgans or of dispersed islet cells. Methods Enzymol. 192, 188–223 (1990).
Kawaki, J. et al. Unresponsiveness to glibenclamide during chronic treatment induced by reduction of ATP-sensitive K+ channel activity. Diabetes 48, 2001–2006 (1999).
Tomizawa, K. et al. Cophosphorylation of amphiphysin I and dynamin I by Cdk5 regulates clathrin-mediated endocytosis of synaptic vesicles. J. Cell Biol. 163, 813–824 (2003).
Acknowledgements
We thank V. Lilla (Louis-Jeantet Research Laboratory, University Medical Center) for providing the MIN6 B1 cell line, H. Noguchi for the technical advice, and T. Ogawa and A. Kemori for technical assistance. This work was supported by a Grant-in-Aid for Scientific Research on Priority Areas “Membrane Traffic” from the Ministry of Education, Science, Sports and Culture of Japan.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Fig. 1
Suppression of Cdk5 expression level by siRNA enhanced insulin secretion in MIN6 cells. (PDF 152 kb)
Supplementary Fig. 2
Reduced phosphorylation level of Ser783 of αlc in the brain and islets of p35-deficient mice. (PDF 184 kb)
Supplementary Fig. 3
Immunostaining of islets in wild-type and p35-knockout mice. (PDF 1086 kb)
Supplementary Fig. 4
Islet mass of wild-type and p35-deficient mice. (PDF 2126 kb)
Rights and permissions
About this article
Cite this article
Wei, FY., Nagashima, K., Ohshima, T. et al. Cdk5-dependent regulation of glucose-stimulated insulin secretion. Nat Med 11, 1104–1108 (2005). https://doi.org/10.1038/nm1299
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm1299
This article is cited by
-
TFP5, a Peptide Derived from Cdk5 Activator p35, Protects Pancreatic β Cells from Glucose Toxicity
Bulletin of Experimental Biology and Medicine (2023)
-
Involvement of Cdkal1 in the etiology of type 2 diabetes mellitus and microvascular diabetic complications: a review
Journal of Diabetes & Metabolic Disorders (2022)
-
The cyclin dependent kinase inhibitor Roscovitine prevents diet-induced metabolic disruption in obese mice
Scientific Reports (2021)
-
Cdk5 drives formation of heterogeneous pancreatic neuroendocrine tumors
Oncogenesis (2021)
-
Blood-based analysis of type-2 diabetes mellitus susceptibility genes identifies specific transcript variants with deregulated expression and association with disease risk
Scientific Reports (2019)